Clinical Trial Update: A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation study evaluating safety, reactogenicity, and immunogenicity of the mRNA-1345 RSV vaccine in healthy adults and RSV-seropositive childr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• mRNA-1345

Snippet

Sponsor: ModernaTX, Inc. | Conditions: Respiratory Syncytial Virus | Phase 1 | Status: COMPLETED